It targets CD19 on B cell malignancies and CD3 on T cells, enabling direct T cell-mediated killing of cancer cells.469 Its success in treating ALL has sparked significant interest in developing similar bispecific antibodies for other types of cancer, including solid tumors. This evidence concerns the gene CD19 and cancer.